T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease Journal Article


Authors: Papadopoulos, E. B.; Carabasi, M. H.; Castro-Malaspina, H.; Childs, B. H.; Mackinnon, S.; Boulad, F.; Gillio, A. P.; Kernan, N. A.; Small, T. N.; Szabolcs, P.; Taylor, J.; Yahalom, J.; Collins, N. H.; Bleau, S. A.; Black, P. M.; Heller, G.; O'Reilly, R. J.; Young, J. W.
Article Title: T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease
Abstract: Thirty-one consecutive patients with acute myelogenous leukemia (AML) in flint complete remission and 8 with AML in second complete remission received T cell-depleted allogeneic bone marrow transplants from HLA-identical sibling donors. Patients received myeloablative cytoreduction consisting of hyperfractionated total body irradiation, thiotepa, and cyclophosphamide. Those patients at risk for immune-mediated graft rejection received additional immune suppression with antithymocyte globulin and methylprednisolone in the early peritransplant period. Patients with AML who underwent allogeneic T-cell-depleted bone marrow transplantations (BMT) in first or second remission have achieved respective disease-free survival (DFS) probabilities of 77% (median follow-up at approximately 56 months) and 50% (median follow-up at approximately 48 months). Ten of 31 patients transplanted In first remission were ≤40 years old end have attained a DIS at 4 years of 70%. For patients with AML transplanted in first or second remission, the respective cause-specific probabilities of relapse were 3.2% or 12.5%, and those of nonleukemic mortality were 19.4% or 37.5%. There were no cases of immune-mediated graft rejection and no cases of grade II to IV acute graft-versus-host disease (GVHD). All survivors enjoy Karnofsky performance scores (KPS) of 100%, except 2 patients with KPS of 80% to 90%. T-cell-depleted allogeneic BMT can provide durable DIS together with an excellent performance status in the majority of patients with de novo AML in addition, GVHD is not an obligatory correlate of the graft-versus-leukemia benefit or freedom from relapse afforded by allogeneic BMT administered as postremission therapy for AML. This study provides a basis for prospective comparison with other postremission therapies considered standard in the management of patients with this disease.
Keywords: adolescent; adult; cancer survival; clinical article; treatment outcome; disease-free survival; acute granulocytic leukemia; t-lymphocytes; cyclophosphamide; allogenic bone marrow transplantation; thiotepa; cancer regression; hla matching; whole body radiation; antineoplastic agents, alkylating; graft versus host reaction; remission induction; methylprednisolone; immunosuppressive treatment; bone marrow transplantation; graft vs host disease; immunosuppressive agents; lymphocyte depletion; transplantation chimera; herpesvirus 4, human; thymocyte antibody; whole-body irradiation; lymphoproliferative disorders; bone marrow purging; leukemia, myelocytic, acute; humans; human; priority journal; article
Journal Title: Blood
Volume: 91
Issue: 3
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 1998-02-01
Start Page: 1083
End Page: 1090
Language: English
PUBMED: 9446672
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus